title: Management of bleeding disorders in children.
abstract: Haemophilia, if not properly managed, can lead to chronic disease and lifelong disabilities. The challenges and issues in infants/young children are different from those in older children and adults although episodes of bleeding still predominate as the diagnostic trigger. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitor development is a challenging complication of paediatric haemophilia and prophylaxis is emerging as the optimal preventive care strategy. In this section we will review some important aspects of haemophilia in children including early prophylaxis, current evidence relating to inhibitor development, including the aims of the SIPPET study which is already ongoing and involves boys <6 years, and the potential of immune tolerance therapy for eradicating the inhibitor and permitting a resumption of standard dosing schedules.
authors.affiliation: Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Berntorp
authors.forename: S
authors.initials: S
authors.lastname: Halimeh
authors.forename: A
authors.initials: A
authors.lastname: Gringeri
authors.forename: M
authors.initials: M
authors.lastname: Mathias
authors.forename: C
authors.initials: C
authors.lastname: Escuriola
authors.forename: R
authors.initials: R
authors.lastname: Pérez
mesh_terms: D019774:Blood Coagulation Factor Inhibitors / Q000276:immunology; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005169:Factor VIII / Q000008:administration & dosage / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007223:Infant
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D005169:Factor VIII